Latest Sunitinib Stories
- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - Phase III trials underway to explore potential of Afinitor in multiple additional cancers EAST HANOVER, N.J., March 30 /PRNewswire/ -- Novartis announced today that Afinitor(R) (everolimus) tablets has been...
NCCN presented new updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Thyroid Carcinoma at the NCCN 14th Annual Conference on March 14.
Pfizer Inc. announced on Thursday that it had halted a successful trial of its cancer drug Sutent after results showed the drug slowed the progression of a rare form of pancreatic cancer.
Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
A British oncologist says he is dismayed that kidney cancer patients may be denied four new treatments due to cost. Dr.
EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, has met the primary endpoint for the efficacy portion of the open label Phase I/II study of MKC-1 in combination with pemetrexed in non-small cell lung cancer patients.
Infinity Pharmaceuticals, a cancer drug discovery and development company, has initiated a Phase III registration trial of IPI-504, its lead inhibitor of heat shock protein 90, in patients with refractory gastrointestinal stromal tumors.
ZymoGenetics, a developer of novel protein therapeutics, has announced positive interim results from a Phase II clinical trial evaluating interleukin 21 in combination with Nexavar tablets in patients with metastatic renal cell cancer.
CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.